Future of ALK inhibition in non-small-cell lung cancer

The Lancet Oncology

Volumn 15, Issue 10, 2014, Pages 1047-1049

  Reckamp, Karen L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ALKALINE PHOSPHATASE; CERITINIB; CRIZOTINIB; PROTEIN TYROSINE KINASE; ROS1 PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE;

CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; NON SMALL CELL LUNG CANCER; NOTE; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; FEMALE; LUNG NEOPLASMS; MALE; SECONDARY;

BRAIN NEOPLASMS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PIPERIDINES;

EID: 84908597186     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70390-0     Document Type: Note

References (10)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
3. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
4. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-1197.
5. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
6. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014, published online Aug 19. http://dx.doi.org/10.1016/S1470-2045(14)70362-6.
7. Maillet D, Martel-Lafay I, Arpin D, Perol M Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol 2013, 8:e30-e31.
8. Prasad V, Massey PR, Fojo T Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 2014, 32:1620-1629.
9. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013, 369:722-731.
10. Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 2014, 32:1412-1418.